Merck Sharp + Dohme Corp.

Acumen Pharmaceuticals, Inc.

Biosen Ma Inc.

Alexander McCampbell

Paul J Shughrue

Weirong Wang

Fubao Wang

Wei-Qin Zhao

Renee C Gaspar

Ningyan Zhang

William F Goure

Min Xu

Mary J Savage

Abigail L Wolfe

Christopher Cody Stebbins

Nigyan Zhang

Wildon Farwell

Franz F Hefti

John Staropoli

Guolin Zhao

Featured are biomarkers for, e.g., diagnosis and prognosis of spinal muscular atrophy (SMA) as well as identification of responders to treatment of SMA. Also provided are methods of treating subjects with SMA.

Methods of treating spinal muscular atrophy

This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.

Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

The present invention relates to antibodies that bind amyloid &#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.

Anti-ADDL monoclonal antibody and uses thereof

This invention is a selective A&#x3b2; oligomer kit and immunoassay method capable of reliably and sensitively detecting A&#x3b2; oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A&#x3b2; oligomer antibodies, as capture and detection antibodies, to detect and quantify A&#x3b2; oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.

Antibodies, kit and method for detecting amyloid beta oligomers

Growing community of inventors

Cambridge, MA, United States of America

Alexander McCampbell